PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-s - Wikidata - wikimedia - TriplyDB

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-s

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-s

http://www.wikidata.org/entity/Q33418542

about

Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study.Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies.Personalized maintenance therapy in advanced non-small cell lung cancer.The challenge of using biomarkers and molecularly targeted drugs to improve cure rate in early stage non-small cell lung cancer Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme Cost Analyses in the US and Japan: A Cross-Country Comparative Analysis Applied to the PRONOUNCE Trial in Non-Squamous Non-Small Cell Lung Cancer.Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review.Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population.Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer.The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.Bevacizumab in advanced lung cancer: state of the art.Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer.Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials.Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine.Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience.Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations.Strategies targeting angiogenesis in advanced non-small cell lung cancer.Bevacizumab in the treatment of NSCLC: patient selection and perspectives.Carboplatin plus pemetrexed for the elderly incurable chemo-naive nonsquamous non-small cell lung cancer: Meta-analysis.Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis.Best Practices in Treatment Selection for Patients With Advanced NSCLC.Antiangiogenic therapies in non-small-cell lung cancer.The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.MicroRNA-137-regulated AKT serine/threonine kinase 2 inhibits tumor growth and sensitizes cisplatin in patients with non-small cell lung cancer.Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma

P2860

Q26767275-788A061B-DBD6-4310-9F0E-0B4067327559 Q26775394-508A5A22-6E94-4277-841A-DAC9BC7EA61B Q30300843-39E1B171-FE79-475D-819A-B04F63B85061 Q33421361-974DB4A2-3D87-4C4C-916A-BB5A0AB6BB0D Q33432327-D6205E1A-BFC5-41F6-BDCE-9C297B7089A6 Q33433360-DA2DAB68-6333-44A7-9C1A-8A67E7AC6A77 Q33439970-00092977-4225-4A55-B4DC-2F2099D2C44E Q33439985-58D30685-51D0-4E7B-9654-78C1AE49FFB7 Q35200455-D63BEEB3-5D26-4B93-B23A-21DBECC05287 Q35290441-F9122F4D-85E9-4559-86AE-699244C77461 Q36008274-A0B36F0F-D38C-45C1-A6FE-05F30A125606 Q36096024-E1E440F1-241D-447D-B5B1-DC8F7444298B Q36373706-B6501B7A-9C1F-4C95-860D-0ACC6B29FF1F Q36927640-9A78AA1C-4316-4BBA-A24A-5A17FFA41D34 Q37042424-A377AE38-37EC-473A-8DB9-F5FD5607D08E Q37152528-9F156688-A58A-4C66-8BAD-42CFF047AC5E Q37532320-98978EEB-DBD7-4B9D-B449-6CC9CABE1460 Q37566838-CB7858FD-264B-4938-B278-36F6FB887DEA Q38155855-9B945FE1-DED8-48BF-9689-432ED339CF5A Q38525073-AA5BFE39-9534-4370-8355-72E265E3D92D Q38641871-9DA2CBB8-1C15-4521-86BA-9B20BDAB7CDC Q38763641-F28BFC4D-9BE8-4CDE-97E7-345D99E6E392 Q38786021-1CA001CB-5638-4904-A673-BA79207ADC76 Q38791974-98A955F3-FC92-48CF-94D7-81285DCCCBC6 Q38829551-61BBC50B-C6B1-49E7-A810-C6A763251939 Q38848914-620150CB-D459-4A22-9ED2-43B1792BEB40 Q38985337-64ABD692-B6F8-4687-8969-50BC84D75927 Q41311492-3C4E87FE-3F78-447E-A7E9-4662522A7F12 Q41593429-DEA3D004-4A4F-4FE1-83E3-2DDEE654E50C Q47168527-0B5BDD34-0A74-475D-9C23-FF2A18ECAE3B Q47188669-BC7C1AA7-314B-45F8-8428-A7DE8CDB39A9 Q47420701-489A3EA8-F4FA-42FB-AFC3-0F467B3545FD Q52814108-B18BBE6F-DAA3-4733-B18A-11D543C6A54A Q55168137-E255B9A3-900D-4FC2-84C7-06E6E18BFAE8 Q55554472-080C6C76-1B7C-4565-A3D6-F3D7EDEB1210 Q55669441-0FB8DD9F-3242-4E0C-8D4D-BC028C07D6BA Q58804445-25F30090-272F-4E96-B544-6C2FE9423A88

P2860

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-s

http://www.wikidata.org/entity/Q33418542

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

PRONOUNCE: randomized, open-la ...... ith advanced nonsquamous non-s

@ast

PRONOUNCE: randomized, open-la ...... ith advanced nonsquamous non-s

@en

type

label

PRONOUNCE: randomized, open-la ...... ith advanced nonsquamous non-s

@ast

PRONOUNCE: randomized, open-la ...... ith advanced nonsquamous non-s

@en

prefLabel

PRONOUNCE: randomized, open-la ...... ith advanced nonsquamous non-s

@ast

PRONOUNCE: randomized, open-la ...... ith advanced nonsquamous non-s

@en

P1433

Q33418542-A7D15C05-2FD8-42FC-B5B8-BA23793FD4C9

P1476

Q33418542-E9807683-9417-4196-B286-E8FD1F308D05

P2093

Q33418542-006A56E7-FE0B-4482-96C7-31FEF426AAD7

Q33418542-2407FAFB-16D6-4EF0-B8F0-610D64C0A1C5

Q33418542-32FECC38-DE68-4EEF-BBEC-6F24A142EB9B

Q33418542-47714148-A2BE-4E0E-BC0F-4B7C5C7BA801

Q33418542-479D9384-56FF-4034-995F-CBA7E5E0BE29

Q33418542-59652121-4EE0-4992-AA48-D87CC2658FEF

Q33418542-59711857-3B4B-4B34-A59C-E1B99324F04D

Q33418542-6A7DD5F9-C0B1-4FF5-87FB-AD97262861E6

Q33418542-735ABB34-A3DC-4C9B-A6D3-3B3FA3C1BCFC

Q33418542-9ACD48C8-DA03-418A-84B0-9DC522F6E797

P2860

Q33418542-099141D8-094F-4895-99A4-C3F9A757AB32

Q33418542-10C0953F-90AC-4D87-A059-686C29E601C2

Q33418542-28926329-0643-4B7D-BA5B-6DE56EA9E7C5

Q33418542-2E3054C3-DED9-458D-9024-33A081E9020A

Q33418542-34B2EC05-7AB1-49D2-85A2-CA1FA761390F

Q33418542-35073E5D-BBC3-43C2-942D-8CEF62856E43

Q33418542-3B0B8907-10EA-40BE-8DE8-F335D9B8646F

Q33418542-41E37983-EECB-4087-B0A3-71A4BEF717D3

Q33418542-4499C377-28B9-42C7-A46A-34065D3119F6

Q33418542-4FCDF0DE-4202-4639-8B85-35F994E0D6BC

P304

Q33418542-2EAC4F57-6B99-48EB-A00D-8EF8C37AAE21

P31

Q33418542-4F3E079F-43D3-4DC0-A050-4C28A388F666

P356

Q33418542-5B73CA42-409F-4D9E-9ABB-EF1C71454C90

P433

Q33418542-B423CFDA-773C-4829-937B-C28C20693C48

P478

Q33418542-BFF5D79D-F80B-4DB4-8503-547973991096

P577

Q33418542-4B9B0F3A-5D20-434A-927B-D95A7E8B741B

P698

Q33418542-E1F7FC30-4348-4B9F-B9E3-E0B63818B2CA

P921

Q33418542-9B710BA3-66BF-4FD5-8767-6DF66C1EE585

P932

Q33418542-7A65B177-6A4D-4AB0-950E-ED3B6E44A2DD

P356

JTO.0000000000000366

P1433

Journal of Thoracic Oncology

P1476

PRONOUNCE: randomized, open-la ...... ith advanced nonsquamous non-s

@en

P2093

Andrew G Koustenis

http://www.w3.org/2001/XMLSchema#string

Borys Hrinczenko

http://www.w3.org/2001/XMLSchema#string

Coleman K Obasaju

http://www.w3.org/2001/XMLSchema#string

David M Waterhouse

http://www.w3.org/2001/XMLSchema#string

David R Spigel

http://www.w3.org/2001/XMLSchema#string

Durisala Desaiah

http://www.w3.org/2001/XMLSchema#string

Helen J Ross

http://www.w3.org/2001/XMLSchema#string

J Thaddeus Beck

http://www.w3.org/2001/XMLSchema#string

Jingyi Liu

http://www.w3.org/2001/XMLSchema#string

Joseph A Treat

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2013

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.

Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.

P304

134-142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JTO.0000000000000366

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25371077

http://www.w3.org/2001/XMLSchema#string

P921

P932

4276572

http://www.w3.org/2001/XMLSchema#string